Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Retained Earnings (2019 - 2025)

C4 Therapeutics' Retained Earnings history spans 7 years, with the latest figure at -$738.7 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 1393860.38% year-over-year to -$738.7 million; the TTM value through Dec 2025 reached -$738.7 million, down 1393860.38%, while the annual FY2025 figure was -$738.7 million, 1393860.38% down from the prior year.
  • Retained Earnings reached -$738.7 million in Q4 2025 per CCCC's latest filing, down from -$718.2 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $455000.0 in Q3 2024 to a low of -$738.7 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$265.7 million, with a median of -$228.4 million recorded in 2021.
  • Peak YoY movement for Retained Earnings: soared 141.73% in 2024, then plummeted 1393860.38% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$775000.0 in 2021, then plummeted by 50982.58% to -$395.9 million in 2022, then soared by 99.97% to -$127000.0 in 2023, then skyrocketed by 141.73% to $53000.0 in 2024, then tumbled by 1393860.38% to -$738.7 million in 2025.
  • Per Business Quant, the three most recent readings for CCCC's Retained Earnings are -$738.7 million (Q4 2025), -$718.2 million (Q3 2025), and -$686.0 million (Q2 2025).